|
1
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Hegi ME, Mason WP, Van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee SM, Tsui SK, Chan KK, Garcia-Barcelo
M, Waye MM, Fung KP, Liew CC and Lee CY: Chromosomal mapping,
tissue distribution and cDNA sequence of four-and-a-half LIM domain
protein 1 (FHL1). Gene. 216:163–170. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bach I: The LIM domain: Regulation by
association. Mech Dev. 91:5–17. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cowling BS, McGrath MJ, Nguyen MA, Cottle
DL, Kee AJ, Brown S, Schessl J, Zou Y, Joya J, Bönnemann CG, et al:
Identification of FHL1 as a regulator of skeletal muscle mass:
Implications for human myopathy. J Cell Biol. 183:1033–1048. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shen Y, Jia Z, Nagele RG, Ichikawa H and
Goldberg GS: SRC uses Cas to suppress Fhl1 in order to promote
nonanchored growth and migration of tumor cells. Cancer Res.
66:1543–1552. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sakashita K, Mimori K, Tanaka F, Kamohara
Y, Inoue H, Sawada T, Hirakawa K and Mori M: Clinical significance
of loss of Fhl1 expression in human gastric cancer. Ann Surg Oncol.
15:2293–2300. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ding L, Wang Z, Yan J, Yang X, Liu A, Qiu
W, Zhu J, Han J, Zhang H, Lin J, et al: Human four-and-a-half LIM
family members suppress tumor cell growth through a TGF-beta-like
signaling pathway. J Clin Invest. 119:349–361. 2009.PubMed/NCBI
|
|
9
|
Lin J, Ding L, Jin R, Zhang H, Cheng L,
Qin X, Chai J and Ye Q: Four and a half LIM domains 1 (FHL1) and
receptor interacting protein of 140kDa (RIP140) interact and
cooperate in estrogen signaling. Int J Biochem Cell Biol.
41:1613–1618. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ding L, Niu C, Zheng Y, Xiong Z, Liu Y,
Lin J, Sun H, Huang K, Yang W, Li X and Ye Q: FHL1 interacts with
oestrogen receptors and regulates breast cancer cell growth. J Cell
Mol Med. 15:72–85. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matsumoto M, Kawakami K, Enokida H, Toki
K, Matsuda R, Chiyomaru T, Nishiyama K, Kawahara K, Seki N and
Nakagawa M: CpG hypermethylation of human four-and-a-half LIM
domains 1 contributes to migration and invasion activity of human
bladder cancer. Int J Mol Med. 26:241–247. 2010.PubMed/NCBI
|
|
12
|
Niu C, Liang C, Guo J, Cheng L, Zhang H,
Qin X, Zhang Q, Ding L, Yuan B, Xu X, et al: Downregulation and
growth inhibitory role of FHL1 in lung cancer. Int J Cancer.
130:2549–2556. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang F, Feng F, Yang P, Li Z, You J, Xie
W, Gao X and Yang J: Four-and-a-half-LIM protein 1 down-regulates
estrogen receptor α activity through repression of AKT
phosphorylation in human breast cancer cell. Int J Biochem Cell
Biol. 44:320–326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu Y, Liu Z and Guo K: Expression of FHL1
in gastric cancer tissue and its correlation with the invasion and
metastasis of gastric cancer. Mol Cell Biochem. 363:93–99. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J,
Nagele RG and Goldberg GS: Coordinate suppression of Sdpr and Fhl1
expression in tumors of the breast, kidney, and prostate. Cancer
Sci. 99:1326–1333. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cao W, Liu J, Xia R, Lin L, Wang X, Xiao
M, Zhang C, Li J, Ji T and Chen W: X-linked FHL1 as a novel
therapeutic target for head and neck squamous cell carcinoma.
Oncotarget. 7:14537–14550. 2016.PubMed/NCBI
|
|
17
|
Wang X, Wei X, Yuan Y, Sun Q, Zhan J,
Zhang J, Tang Y, Li F, Ding L, Ye Q and Zhang H: Src-mediated
phosphorylation converts FHL1 from tumor suppressor to tumor
promoter. J Cell Biol. 217:1335–1351. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dey N, Crosswell HE, De P, Parsons R, Peng
Q, Su JD and Durden DL: The protein phosphatase activity of PTEN
regulates SRC family kinases and controls glioma migration. Cancer
Res. 68:1862–1871. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakamura JL, Garcia E and Pieper RO: S6K1
plays a key role in glial transformation. Cancer Res. 68:6516–6523.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Y, Ma X, Wang Y and Li G: miR-489
inhibits proliferation, cell cycle progression and induces
apoptosis of glioma cells via targeting SPIN1-mediated PI3K/AKT
pathway. Biomed Pharmacother. 93:435–443. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nan Y, Guo L, Song Y, Wang L, Yu K, Huang
Q and Zhong Y: Combinatorial therapy with adenoviral-mediated PTEN
and a PI3K inhibitor suppresses malignant glioma cell growth in
vitro and in vivo by regulating the PI3K/AKT signaling pathway. J
Cancer Res Clin Oncol. 143:1477–1487. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bayne K: Revised Guide for the Care and
Use of Laboratory Animals available. American Physiological
Society. Physiologist. 39:199, 208–211. 1996.
|
|
23
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang H, Yan X, Ji LY, Ji XT, Wang P, Guo
SW and Li SZ: miR-139 functions as an antioncomir to repress glioma
progression through targeting IGF-1 R, AMY-1, and PGC-1β. Technol
Cancer Res Treat. 16:497–511. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang YT, Yuan B, Chen HD, Xu L, Tian YN,
Zhang A, He JX and Miao ZH: Acquired resistance of phosphatase and
tensin homolog-deficient cells to poly(ADP-ribose) polymerase
inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1
overexpression. Cancer Sci. 109:821–831. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han L, Yang Y, Yue X, Huang K, Liu X, Pu
P, Jiang H, Yan W, Jiang T and Kang C: Inactivation of PI3K/AKT
signaling inhibits glioma cell growth through modulation of
β-catenin-mediated transcription. Brain Res. 1366:9–17. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Goodwin CR, Lal B, Zhou X, Ho S, Xia S,
Taeger A, Murray J and Laterra J: Cyr61 mediates hepatocyte growth
factor-dependent tumor cell growth, migration, and Akt activation.
Cancer Res. 70:2932–2941. 2010. View Article : Google Scholar : PubMed/NCBI
|
